RC110 is a bisantrene chemotherapy drug which was already approved in France in 1990 for use in AML and RAC conducted the Ph1b/2 clinical trial for AML in combination with other SoC chemotherapy drugs and demonstrated this work (unsurprisingly since it has already been approved over 3 decades ago) but now is still waiting for their own RC220 (I've been told this is similar to RC110) to receive ethic approval in the last few months and start Ph1 clinical trial with SoC chemotherapy drug.
@Mason14's argument is this make his investment low risk as he has countless excellent Ph2 clinical trials for bisantrene in the last 5 decades but BP or R&D companies hasn't bother to advance the IP even after RC110 was approved over 3 decades ago so there's big question around commercial viability and valuation especially since RC220 isn't replacing SoC but is combined with chemotherapy drug doxorubicin which has been used for 5 decades instead of bisantrene. I highly doubt he didn't sell RAC when the MC was way overvalue $750M for just Ph1b/2 clinical trial for RC110 and is free carrying right now on a large holding and will trade them on clinical trial update (unsurprisingly they will be positive).
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)